Published Jun 18, 2024

Labshares Announces Key Leadership Additions: Devon Lagasse Joins as VP of Growth and Emma Orfanos Is Promoted to Manager of Business Development

Press Releases

Newton, MA – June 2024

Labshares, a premier shared laboratory for emerging biotech and life science companies, is excited to announce two significant additions to its leadership team. Devon Lagasse has been appointed as Labshares’ new Vice President of Growth, and Emma Orfanos has been promoted to Manager of Business Development.

Devon Lagasse Joins Labshares as VP of Growth

Devon Lagasse brings a wealth of relevant experience to the position. With over 13 years at Eppendorf and MSD, Devon has a proven track record of developing deep relationships within the biotech and life science industry, expanding market presence, and driving growth. Her expertise will be invaluable as Labshares continues to expand its service offerings and footprint.

 

"We are thrilled to welcome Devon to our team," said Philip Borden, CEO of Labshares.

"Her extensive industry knowledge and vision will be critical as we scale our operations and enhance our offerings to emerging biotech and life science companies. Devon will undoubtedly help us grow and reinforce Labshares’ position as the leading provider of shared lab services in Greater Boston."  said Phillip Borden, CEO of labshares.

Emma Orfanos Promoted to Manager of Business Development

Labshares is also proud to announce the promotion of Emma Orfanos to the role of Manager of Business Development. Emma has been with Labshares for two and a half years, during which time she has demonstrated exceptional leadership and an ability to build and maintain relationships with Labshares members. She understands the needs of life science startups and her dedication to their success makes her a critical asset to the team.

"Emma's promotion is a testament to her hard work and outstanding contributions to Labshares," said Borden.

"Emma has been instrumental in Labshares’ strong historic growth and she’ll continue to play a pivotal role in expanding our network and ensuring the success of our member companies."  said Phillip Borden, CEO of labshares.

Related or similar articles

March 13, 2019

Labshares Newton Grows its Business​

Labshares is unveiling a major rennovation
Labshares News
August 19, 2019

Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company ...
Member News
August 8, 2018

Harbour BioMed inks $350 million deal for rights to A167

USA-based Harbour BioMed has entered into an exclusive strategic partnership with China’s Sichuan Kelun-Biotech Biopharmaceutical to develop and commercialize A167
Member News